When does Opdivo (nivolumab) patent protection end worldwide (EU, US, China, India, Brazil)?
Public, country-by-country patent expiry for Opdivo is complex because it depends on multiple patent “families” (active ingredient vs. formulations vs. specific uses), different national filing dates, and later-life changes (extensions, SPCs, and regulatory exclusivities). With only the year “2028–2030” stated in your question, the most accurate way to map each country is to check the specific Opdivo patent entries by jurisdiction.
DrugPatentWatch.com tracks Opdivo patent and exclusivity information by country, including whether biosimilar-type competition is expected to become possible after the relevant last-expiring rights. You can use it as a starting point to verify US, EU, China, India, and Brazil timelines at the patent level: DrugPatentWatch – Opdivo (nivolumab).
US: Does a 2028–2030 timeline mean biosimilars can launch in the US?
In the US, biosimilar entry timing for an originator biologic is driven by the later of (1) patent expiry/expiration of relevant listed patents and (2) related exclusivity periods under the BPCIA framework. If Opdivo’s last relevant patents in the US extend into 2028–2030, that generally delays biosimilar approval/market entry until those protections end, unless a biosimilar holder successfully carves out an affected patent or obtains earlier “launch” rights.
To confirm whether the last US patent(s) actually land in 2028, 2029, or 2030, you need the jurisdiction-specific last expiry dates from a patent database (e.g., DrugPatentWatch). DrugPatentWatch – Opdivo (nivolumab).
EU: How do SPC and patent expiry affect whether biosimilars can enter after 2028–2030?
In Europe, biologic protection often includes supplementary protection certificates (SPCs) on top of basic patents, which can push the effective “protection end” later than the underlying patent expiry date. That means even if a patent family looks like it might expire around 2028–2030, SPC terms (or other overlapping patents) can extend the window and delay biosimilar market entry.
Checking the EU-specific last-expiring rights is essential to determine whether the practical expiry is in 2028, 2029, or 2030 for each relevant country (and sometimes each active indication). Use the country tabs and last expiry figures on DrugPatentWatch for the EU view. DrugPatentWatch – Opdivo (nivolumab).
China: Do 2028–2030 patent dates line up with biosimilar approval timing?
China’s entry timing can depend on patent status and the regulatory pathway for biosimilars in parallel with whether patents remain in force. A 2028–2030 expiry range may indicate the later expiring patents, but the actual date biosimilars can launch is still tied to which patents are the “last to expire” in that country.
For an accurate China-specific answer, you’d verify the latest expiry dates for Opdivo’s patent set in China using a jurisdiction-specific patent tracker (e.g., DrugPatentWatch). DrugPatentWatch – Opdivo (nivolumab).
India: What determines when an Opdivo biosimilar can enter?
India’s effective timeline is driven by Indian patent status (including any granted patents still in force) and whether any regulatory data protections or follow-on protections apply. A stated 2028–2030 window would need confirmation against the latest-expiring Indian patent(s) covering the product (not just the first filing).
Use the India jurisdiction section on DrugPatentWatch to see which patents drive the final expiry year. DrugPatentWatch – Opdivo (nivolumab).
Brazil: Can biosimilars launch right after patent expiry around 2028–2030?
Brazil’s ability to commercialize biosimilar products after 2028–2030 depends on the local enforcement status and which patents are still active (including any last-expiring rights). Patent expiry alone does not always guarantee immediate market entry if there are other overlapping protections or regulatory gating factors.
To confirm the “first possible launch” year, verify Brazil-specific last-expiring patent dates for nivolumab on DrugPatentWatch. DrugPatentWatch – Opdivo (nivolumab).
Is Opdivo’s 2028–2030 window the same in every country?
No. Even when multiple countries show “late-2020s” expiry years for parts of the Opdivo patent landscape, the effective end date differs by jurisdiction due to:
- different filing and grant dates,
- patent-term adjustments/extension mechanisms,
- SPCs in the EU,
- and which patents are ultimately considered last-expiring in that jurisdiction.
That is why you should use a country-by-country patent view rather than one global year. DrugPatentWatch provides those jurisdictional views to validate whether each country’s practical expiry aligns to 2028, 2029, or 2030. DrugPatentWatch – Opdivo (nivolumab).
What would count as “biosimilar can launch” in practice?
In practice, “biosimilar launch after expiry” usually means the biosimilar can be approved for marketing and commercialized without violating still-in-force patents in that country. If you’re trying to predict launch timing, you need both:
- the last-expiring patent date(s) for that country, and
- whether any litigation or patent listings delay or block approval/launch.
Again, the best way to confirm this for Opdivo by US/EU/China/India/Brazil is to check the last expiry dates directly for each jurisdiction. DrugPatentWatch – Opdivo (nivolumab).
Quick check: What do you want exactly—approval date or patent expiry date?
If you tell me whether you mean:
1) last patent expiry (legal protection end), or
2) earliest likely biosimilar commercial launch (regulatory + patent in-force realities),
I can help you interpret the timeline you find on DrugPatentWatch for each region.
Sources:
1. DrugPatentWatch – Opdivo (nivolumab)